Table 1. DMD characteristics included and excluded in the patient decision aid
Characteristic | BWS RIS Mean (SD) | New categorization of characteristic |
|---|---|---|
Included in the patient decision aid | Â | Â |
Effect on relapse rate | 7.76 (2.58) | Effect on relapses |
Effect on the severity of relapse | 7.39 (2.32) | |
Safety | 6.04 (2.95) | Safety (risk of severely disabling and life-threatening adverse events) |
Uncertainty about long-term consequences | 4.58 (2.76) | |
Required monitoring | 0.55 (1.18) | Required monitoring |
Severity of side effects | 7.63 (2.11) | Risk of common side effects |
Type of side effects | 5.00 (2.71) | |
Duration of side effects | 3.74 (1.97) | |
Influence on life style | 5.31 (2.92) | Ease of use |
Mode of administration | 1.58 (2.69) | |
Frequency of administration | 0.68 (1.38) | |
Duration of administration | 0.20 (0.24) | |
Effect on disability progression | 9.64 (1.16) | Effect on disability progression (based on EDSS) |
Effect on QoL | 9.21 (1.45) | Effect on QoL (based on PRO) |
Effect on development of plaques in the brain | 7.31 (2.52) | Effect on development of plaques in the brain |
Effect on current MS symptoms | 7.32 (1.97) | Effect on fatigue (based on PRO) |
| Â | Â | Effect on cognition (based on PRO) |
Omitted from the patient decision aid | Â | Â |
Effect on life expectancy | 4.81 (3.13) | Â |
Pace of effect | 3.18 (2.19) | Â |
Interaction with other medication | 1.72 (1.86) | Â |
Insurance coverage | 2.71 (2.87) | Â |
Mode of action of DMD | 0.99 (1.25) | Â |
Total DMD costs | 0.86 (1.27) | Â |
Further development of DMD | 0.87 (0.94) | Â |
Composition of DMD | 0.18 (0.36) | Â |
Use of DMD among other MS patients | 0.34 (0.56) | Â |
Ease of travelling | 0.29 (0.87) | Â |
Contact person at pharmaceutical company | 0.10 (0.28) | Â |